TTrialPathMatch Me to Trials
← Back to trials
RecruitingHidradenitis Suppurativa (HS)

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Eligible age

18+ yrs

Accepts

All genders

Locations

28 states

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.

Sponsor: Incyte Corporation

You may qualify if…

  • ✓ Ability to comprehend and willingness to sign a written ICF for the study.
  • ✓ Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
  • ✓ Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
  • ✓ Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
  • ✓ Willingness to avoid pregnancy or fathering children as defined in the protocol.
  • ✓ Willingness and ability to comply with the study Protocol and procedures.

You may not qualify if…

  • ✕ Had been permanently discontinued from study treatment during the parent study.
  • ✕ Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
  • ✕ Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:
  • ✕ Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
  • ✕ Live, attenuated vaccine.
  • ✕ Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug.
  • ✕ Women who are pregnant (or who are considering pregnancy) or breastfeeding.
  • ✕ Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class.

Where it's recruiting

Alabama

Birmingham · Montgomery

Arizona

Phoenix · Tucson

California

Fountain Valley · Fremont · Huntington Beach · Irvine …

Connecticut

Farmington

Florida

Boca Raton · Coral Gables · Hialeah · Hollywood …

Georgia

Cumming · Marietta · Sandy Springs · Stonecrest

Illinois

Chicago · Skokie · West Dundee

Indiana

Indianapolis · West Lafayette

Kansas

Leawood

Kentucky

Bowling Green

Louisiana

Baton Rouge · New Orleans

Maryland

Baltimore · Glenn Dale · Rockville

Source: ClinicalTrials.gov · NCT06855498 · last updated 2026-11-13